5,669 results match your criteria Annales D Endocrinologie[Journal]


Efficacy and tolerance of recombinant growth hormone treatment in children with growth retardation related to long-term glucocorticosteroid therapy.

Ann Endocrinol (Paris) 2019 Mar 4. Epub 2019 Mar 4.

Pfizer PGRD, Sandwich, United Kingdom.

Objective: To evaluate tolerance and efficacy of recombinant human growth hormone treatment in children on long-term glucocorticoid therapy.

Methods: A 5-year prospective open-label study included children on glucocorticoid therapy with bone age<15 years for boys and<13 years for girls and either standard deviation score (SDS)<-2 for height for chronological age (CA) if naïve to growth hormone treatment, or annual growth rate≥0 SDS for CA if currently receiving growth hormone.

Results: Ninety-eight patients began treatment, 63 discontinued; 59 were analyzed for tolerance and 58 for efficacy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2019.02.001DOI Listing
March 2019
1 Read

Graves' disease as a first autoimmune manifestation of a stiff person syndrome.

Ann Endocrinol (Paris) 2019 Apr 14;80(2):134-136. Epub 2019 Feb 14.

Department of endocrinology and diabetology, CHU UCL Namur, Université Catholique de Louvain, rue Dr. Gaston Thérasse 1, 5530 Yvoir, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2019.01.002DOI Listing
April 2019
1 Read

Small molecules and extrinsic factors promoting differentiation of stem cells into insulin-producing cells.

Ann Endocrinol (Paris) 2019 Apr 29;80(2):128-133. Epub 2019 Jan 29.

Department of Endocrinology, the Second Affiliated Hospital of Nanchang University, No. 1, Minde Road, Jiangxi Province, 330006 Nanchang, China. Electronic address:

In the modern world, type-2 diabetes mellitus has become a leading public healthcare problem, due to major risks of morbidity and mortality. Prevalence has increased significantly in recent decades. Treatment involves oral hypoglycemic agents or insulin replacement therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.11.002DOI Listing
April 2019
3 Reads

The SURCOUF study: Design and baseline characteristics of a prospective population-based cohort on diabetes care in France.

Ann Endocrinol (Paris) 2019 Apr 29;80(2):136-137. Epub 2019 Jan 29.

Service d'endocrinologie, maladies métaboliques et nutrition, hôpital Saint-Pierre, CHU de la Réunion, 97448 Saint-Pierre. France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.11.005DOI Listing
April 2019
2 Reads

Functioning gonadotroph adenoma with severe ovarian hyperstimulation syndrome: A new emergency in pituitary adenoma surgery? Surgical considerations and literature review.

Ann Endocrinol (Paris) 2019 Apr 7;80(2):122-127. Epub 2019 Feb 7.

Department of neurosurgery, hôpital La Timone, Assistance publique-Hôpitaux de Marseille (AP-HM), Marseille, France; Aix-Marseille université, institut national de la santé et de la recherche médicale (Inserm), U1251, Marseille medical genetics (MMG), Marseille, France.

The authors reported 2 cases of functioning gonadotroph pituitary adenoma (FGPA) revealed by an ovarian hyperstimulation syndrome (OHSS) in young women. In the first case, OHSS was observed after GnRH analog injection. Pelvic echography revealed multiple voluminous ovarian cysts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.11.007DOI Listing
April 2019
2 Reads

Circulating Vascular Cell Adhesion Molecule-1 (VCAM-1) and Intercellular Adhesion Molecule-1 (ICAM-1): Relationship with carotid artery elasticity in patients with impaired glucose regulation (IGR).

Ann Endocrinol (Paris) 2019 Apr 7;80(2):72-76. Epub 2019 Feb 7.

Department of Blood Supply, Zaozhuang Central Blood Station, No. 44 Wenhuazhong Road Shizhong District, 277100 Zaozhuang, Shandong, China. Electronic address:

Objective: To investigate the relations of circulating adhesion molecule vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) with carotid artery elasticity in patients with impaired glucose regulation (IGR).

Methods: A total of 208 subjects were enrolled from January 2013 to March 2014. One hundred forty-eight were IGR patients, and 60 had normal glucose tolerance (NGT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2019.01.001DOI Listing

Case report: Ectopic ACTH secretion due to a metastatic atypical lung carcinoid tumor. From diagnosis to treatment.

Ann Endocrinol (Paris) 2019 Apr 29;80(2):137-139. Epub 2019 Jan 29.

Endocrinology, Clinique Saint Luc de Bouge, UCL, 8, rue Saint-Luc, 5004 Bouge, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.11.004DOI Listing
April 2019
1 Read

Letter to the editor: A case of laboratory-generated "thyroid dysfunction".

Ann Endocrinol (Paris) 2019 Apr 31;80(2):140-141. Epub 2018 Oct 31.

Fédération d'endocrinologie, CHU de Lyon, 59, boulevard Pinel, 69677 Bron, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.10.001DOI Listing

Differential expression of a set of microRNA genes reveals the potential mechanism of papillary thyroid carcinoma.

Ann Endocrinol (Paris) 2019 Apr 13;80(2):77-83. Epub 2018 Oct 13.

Department of nuclear medicine, The Third Affiliated Hospital of Kunming Medical University, Yunnan Provincial Tumor Hospital, Kunming, 650118, China. Electronic address:

Background: Our aim was to explore the potential mechanism underlying papillary thyroid carcinoma (PTC) development.

Methods: Gene expression profile data GSE3467 and microRNA (miRNA) expression profile data E-TABM-68 were downloaded from Gene Expression Omnibus and Array Express database respectively. The differentially expressed genes (DEGs) and miRNAs between PTC patients and normal individuals were screened. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.07.014DOI Listing
April 2019
3 Reads

Daily life, needs and expectations of patients with acromegaly in France: An on-line survey.

Ann Endocrinol (Paris) 2019 Apr 25;80(2):110-116. Epub 2018 Sep 25.

Service d'endocrinologie, diabète-nutrition, CHU de Reims, 51092 Reims cedex, France.

Acromegaly can impair quality of life, but impact on patients' daily life, needs and expectations have been poorly explored.

Objectives: To better understand the impact of acromegaly on patients' daily life, and evaluate their needs and expectations.

Patients And Methods: An on-line questionnaire survey of acromegaly patient and relative community members was conducted on the Carenity website. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00034266183124
Publisher Site
http://dx.doi.org/10.1016/j.ando.2018.08.006DOI Listing
April 2019
9 Reads

Does hemithyroidectomy still provide any benefit?

Ann Endocrinol (Paris) 2019 Apr 25;80(2):101-109. Epub 2018 Sep 25.

Service de chirurgie viscérale et endocrinienne, CHU d'Angers, 4, rue Larrey, 49100 Angers, France.

Objectives: Multinodular goiter is a common disorder, found in 5% of the general population. If only one thyroid lobe is affected, hemithyroidectomy may be preferred to total thyroidectomy, to limit the risk of complications and avoid hormone replacement therapy, but incurs a risk of subsequent completion thyroidectomy. The aim of the present study is to determine whether the arguments in favor of hemithyroidectomy are justified and whether it still provides real benefit. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00034266183125
Publisher Site
http://dx.doi.org/10.1016/j.ando.2018.09.006DOI Listing
April 2019
16 Reads

Graves' disease: Introduction, epidemiology, endogenous and environmental pathogenic factors.

Ann Endocrinol (Paris) 2018 Dec 11;79(6):599-607. Epub 2018 Sep 11.

Service d'endocrinologie-diabétologie-nutrition, CHU de Pointe-à-Pitre, route de Chauvel, 97159 Pointe-à-Pitre, France. Electronic address:

Graves' disease is the most frequent cause of hyperthyroidism. Many questions remain about the choice of diagnostic evaluations and treatment strategy according to clinical context (age, gender, pregnancy, etc.) and about the best management of the main extrathyroidal complication that is Graves orbitopathy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.09.002DOI Listing
December 2018
20 Reads

Primary adrenal insufficiency and hemochromatosis - Cause and effect relationship or a coincidence?

Ann Endocrinol (Paris) 2019 Feb 16;80(1):64-67. Epub 2018 Oct 16.

2nd Department of radiology, medical university of Gdansk, Debinki street 7, 80-211 Gdansk, Poland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.01.004DOI Listing
February 2019
2 Reads

The Graves' disease, consensus of the French Society of Endocrinology.

Ann Endocrinol (Paris) 2018 Dec 11;79(6):597-598. Epub 2018 Sep 11.

Service EDN, centre de référence des maladies rares de la thyroïde et des recepteurs hormonaux, CHU d'Angers, 4, rue Larrey, 49000 Angers, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.09.003DOI Listing
December 2018
18 Reads

Association between KISS1 rs5780218 promoter polymorphism and onset of growth hormone secreting pituitary adenoma.

Ann Endocrinol (Paris) 2019 Apr 25;80(2):96-100. Epub 2018 Sep 25.

Laboratorio de Endocrinologia Celular e Molecular, LIM25, Disciplina de Endocrinologia e Metabologia, Hospital das Clinicas, FMUSP, São Paulo, Brasil; Unidade de Neuroendocrinologia, Disciplina de Endocrinologia e Metabologia, Hospital das Clinicas, FMUSP, São Paulo, Brasil. Electronic address:

Objectives: This study analyzed the KISS1 c.-145delA (rs5780218) promoter polymorphism in a cohort of patients with growth hormone secreting pituitary adenoma (somatotropinoma) and controls, to investigate its role in the incidence of acromegaly and to assess patient/tumor characteristics. Material and methods rs5780218 allelic and genotypic distributions were compared between 49 somatotropinoma patients and 167 healthy controls. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00034266183125
Publisher Site
http://dx.doi.org/10.1016/j.ando.2018.09.007DOI Listing
April 2019
5 Reads

Pasireotide: A potential therapeutic alternative for resistant prolactinoma.

Ann Endocrinol (Paris) 2019 Apr 25;80(2):84-88. Epub 2018 Sep 25.

Centre de référence maladies rares hypophysaires (HYPO), fédération d'endocrinologie, groupement hospitalier Est, hospices civils de Lyon, 69677 Bron, France; Faculté de médecine Lyon Est, université Lyon 1, 69372 Lyon, France; Inserm U1052, CNRS UMR5286, Cancer Research Centre of Lyon, 69372 Lyon, France. Electronic address:

Context: About 10% of prolactinomas are resistant to dopamine-agonists (DAs). The only alternatives for tumor and prolactin control are surgery or radiotherapy. While studies on first generation somatostatin analogs have shown no efficacy against prolactinomas, no study has been conducted on the new multireceptor-targeted somatostatin receptor ligand pasireotide, which presents high affinity for 5, 3, 2 and 1 receptor subtypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.07.013DOI Listing
April 2019
2 Reads

Isolated elevation of thyroglobulin in the follow-up of differentiated thyroid cancer, does it always indicate true persistent disease?

Ann Endocrinol (Paris) 2019 Feb 25;80(1):61. Epub 2018 Sep 25.

Fédération d'endocrinologie, CHU de Lyon, 59, boulevard Pinel, 69677 Bron, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.09.005DOI Listing
February 2019

TRα inhibits arterial renin-angiotensin system expression and prevents cholesterol accumulation in vascular smooth muscle cells.

Ann Endocrinol (Paris) 2019 Apr 25;80(2):89-95. Epub 2018 Sep 25.

Platform ANIPHY, University Claude Bernard Lyon 1, 69008 Lyon, France. Electronic address:

Objectives: The tissue renin-angiotensin system (tRAS) plays a key role in the maintenance of cellular homeostasis but is also implicated in atherosclerosis. Thyroid hormone (TH) contributes, via genomic effects, to control of tRAS gene expression in the arterial wall and vascular smooth muscle cells (VSMCs). We investigated the specific functions of TH receptors-α and -β (TRα and TRβ) on tRAS gene expression in the aorta and VSMCs, and the potential protective effect of TRα against atherosclerosis. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00034266183125
Publisher Site
http://dx.doi.org/10.1016/j.ando.2018.09.008DOI Listing
April 2019
3 Reads

Expression of β-endorphin in peripheral tissues after systemic administration of lipopolysaccharide as a model of endotoxic shock in mice.

Ann Endocrinol (Paris) 2019 Apr 19;80(2):117-121. Epub 2018 Sep 19.

Department of Dental Anesthesiology and Pain Management, Tohoku University Hospital, 4-1 Seiryo-machi, Aoba-ku, 980-8575, Sendai, Japan.

Background: Endogenous β-endorphin is delivered exclusively from the pituitary gland in various stressful conditions and plays an essential role in the nervous system. Recently, a few studies demonstrated peripheral endogenous opioid secretion from immune cells at inflammatory sites. Here, we investigated the expression of β-endorphin, the most powerful endogenous opioid peptide, in peripheral tissues in response to systemic administration of lipopolysaccharide in mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.06.001DOI Listing

Leptin regulates neuropeptides associated with food intake and GnRH secretion.

Ann Endocrinol (Paris) 2019 Feb 11;80(1):38-46. Epub 2018 Aug 11.

Departamento de Reproducción, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, Mexico D.F.

The present review focused on the most important effects of leptin on the hypothalamus and on how leptin regulates neuropeptides associated with food intake and GnRH secretion. This review of the literature suggests that a reduction in leptin serum concentrations results from lower body energy reserves or poor energy availability, leading to hypothalamic secretion of neuropeptides such as NPY/AgRP and QRFP to stimulate food intake. Under these negative metabolic conditions, GnRH secretion is reduced, impairing reproductive functions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.07.012DOI Listing
February 2019

Bilateral adrenalectomy in Cushing's disease: Altered long-term quality of life compared to other treatment options.

Ann Endocrinol (Paris) 2019 Feb 19;80(1):32-37. Epub 2018 Sep 19.

Fédération d'endocrinologie, groupement hospitalier Est, hospices civils de Lyon, 59, boulevard Pinel, 69677 Lyon, France; Inserm U1052, CNRS UMR5286, Lyon I university, signaling, metabolism and tumor progression, cancer center of Lyon, centre Léon-Bérard, bâtiment Cheney D-5th Floor, 28, rue Laennec, 69008 Lyon, France.

Objective: Bilateral adrenalectomy (BADX) has become an important treatment of Cushing's disease (CD), especially when other treatment options have failed. The aim of this study was to evaluate the long-term quality of life (QoL) of patients having undergone BADX for CD, in comparison to other therapeutic options.

Methods: Thirty-four patients with CD were identified in two French centers: 17 underwent BADX and the remaining 17 one or more of the following treatments: surgery, medical therapy or radiotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.01.002DOI Listing
February 2019
2 Reads

UCP1 transrepression in Brown Fat in vivo and mineralocorticoid receptor anti-thermogenic effects.

Ann Endocrinol (Paris) 2019 Feb 17;80(1):1-9. Epub 2018 Sep 17.

Inserm U1185, Faculté de Médecine Paris-Sud, Université Paris-Sud, Université Paris-Saclay, 94276 Le Kremlin-Bicêtre, France; Service d'endocrinologie et des maladies de la reproduction, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris, 94275 Le Kremlin-Bicêtre, France. Electronic address:

Objectives: The mineralocorticoid receptor (MR), a hormone-activated transcription factor, besides its role in controlling hydroelectrolytic homeostasis, exerts pro-adipogenic and anti-thermogenic effects, inhibiting mitochondrial-uncoupling protein UCP1 expression in brown adipocytes. The aim of this study was to gain insight into the molecular mechanisms by which MR participates in such metabolic regulation.

Methods: We evaluated in vivo MR effects on cold-induced UCP1 expression in MR-overexpressing mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.04.018DOI Listing
February 2019
10 Reads

Issues in amiodarone-induced thyrotoxicosis: Update and review of the literature.

Ann Endocrinol (Paris) 2019 Feb 17;80(1):54-60. Epub 2018 Sep 17.

Service d'endocrinologie, diabétologie et maladies métaboliques, CHU Clermont-Ferrand, 63003 Clermont-Ferrand, France; Laboratoire GReD, UMR Université Clermont Auvergne-CNRS 6293, Inserm U1103, BP 10448, 63177 Aubière, France.

Amiodarone, a benzofuranic iodine-rich pan-anti-arrhythmic drug, induces amiodarone-induced thyrotoxicosis (AIT) in 7-15% of patients. AIT is a major issue due to its typical severity and resistance to anti-thyroid measures, and to its negative impact on cardiac status. Classically, AIT is either an iodine-induced thyrotoxicosis in patients with abnormal thyroid (type 1), or due to acute thyroiditis in a "healthy" thyroid (type 2). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.05.001DOI Listing
February 2019
3 Reads

Graves' disease and pregnancy.

Ann Endocrinol (Paris) 2018 Dec 16;79(6):636-646. Epub 2018 Aug 16.

Service de médecine nucléaire, hospices civils de lyon, groupement hospitalier Est, 69677 Bron cedex, France.

This section deals with the specificities of managing Graves' disease during pregnancy. Graves' disease incurs risks of fetal, neonatal and maternal complications that are rare but may be severe: fetal hyper- or hypothyroidism, usually first showing as fetal goiter, neonatal dysthyroidism, premature birth and pre-eclampsia. Treatment during pregnancy is based on antithyroid drugs alone, without association to levothyroxine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.08.004DOI Listing
December 2018
16 Reads

Diagnostic procedure in suspected Graves' disease.

Ann Endocrinol (Paris) 2018 Dec 18;79(6):608-617. Epub 2018 Aug 18.

Service d'endocrinologie, CHU de Rabat, Rabat, Morocco.

Diagnostic procedure in suspected Graves' disease has never been studied scientifically and actual practice seems quite variable, notably between countries. Recommendations are few and weak (expert opinion). This article presents the recommendations of an expert consensus meeting organized by the French Society of Endocrinology in 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.08.002DOI Listing
December 2018
1 Read

[Bone and metabolism].

Ann Endocrinol (Paris) 2018 Sep;79 Suppl 1:S40-S47

Fédération d'endocrinologie, diabétologie et maladies métaboliques, hôpital Louis-Pradel, 59, boulevard Pinel, 69500 Bron, France.

Bone is now considered as a particular endocrine organ. Its endocrine function is not yet fully understood and has been the subject of several conferences at the European Society of Endocrinology Congress 2018. Bone regulates phosphate metabolism by secreting fibroblast growth factor 23; it also regulates glucose metabolism via osteocalcin and energy metabolism, thanks to lipocalin 2, a new hormone acting on the brain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0003-4266(18)31236-8DOI Listing
September 2018
3 Reads

[New perspectives for the diagnosis and prognosis of Graves' disease].

Ann Endocrinol (Paris) 2018 Sep;79 Suppl 1:S31-S39

Service d'endocrinologie, Hôpital Avicenne, AP-HP, 125, rue de Stalingrad, 93009 Bobigny Cedex, France.

Graves' thyroiditis is a frequent disease. It has a considerable impact on patient's life quality and health expenses. Thus, it is important to optimize the treatment and follow up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0003-4266(18)31239-3DOI Listing
September 2018
1 Read

[Differences of Sex Development (DSD): Controversies and Challenges].

Ann Endocrinol (Paris) 2018 Sep;79 Suppl 1:S22-S30

Service d'endocrinologie pédiatrique, Assistance publique des hôpitaux de Paris, CHU de Bicêtre, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre; Centre de référence maladies rares du développement génital, faculté de médecine, Paris-Sud, 63, rue Gabriel-Péri, 94276 Le Kremlin Bicêtre.

DSD for "Differences of Sex Development" or "Sexual Differences Development" refers to situations where chromosomal, gonadal or anatomical sex is atypical. DSD 46,XX are mainly represented by congenital adrenal hyperplasia (HCS) and are not a diagnostic issue. DSD 46,XY involve genes for the determination and differenciation of the bipotential gonad, making sometimes difficult the choice of sex at birth. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0003-4266(18)31235-6DOI Listing
September 2018
9 Reads

[Hereditary pheochromocytoma and paraganglioma: screening and follow-up strategies in asymptomatic mutation carriers].

Ann Endocrinol (Paris) 2018 Sep;79 Suppl 1:S10-S21

Aix-Marseille université, Institut national de la santé et de la recherche médicale (INSERM), U1251, Marseille Medical Genetics (MMG), Marseille, France; Assistance publique-Hôpitaux de Marseille (AP-HM), département d'endocrinologie, hôpital de la Conception, centre de référence des maladies rares de l'hypophyse HYPO, 13005, Marseille, France. Electronic address:

The management of pheochromocytoma and paraganglioma has deeply evolved over the last years due to the discovery of novel genes of susceptibility, especially SDHx, MAX and TMEM127. While the modalities of diagnosis and management of patients presenting with hereditary pheochromocytoma and paraganglioma are now well defined, screening and follow-up strategies for asymptomatic mutation carriers remain a matter of debate. This raises major questions as these asymptomatic patients will require a lifelong follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0003-4266(18)31234-4DOI Listing
September 2018
6 Reads

[Semen quality and fertility: the role of the environment and health].

Ann Endocrinol (Paris) 2018 Sep;79 Suppl 1:S1-S9

Service d'endocrinologie, hôpital Saint-Antoine, Assistance publique-Hôpitaux de Paris, 75012 Paris, France.; Sorbonne Université, 75006 Paris, France.

Sperm quality appears to be degrading over the past 40 years. Nowadays, more than 35 % of causes of male infertility are still idiopathic. More and more studies have suggested an impact of environment on sperm quality, essentially through epigenetic and hormonal changes. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00034266183123
Publisher Site
http://dx.doi.org/10.1016/S0003-4266(18)31233-2DOI Listing
September 2018
1 Read

Treatment of adult Graves' disease.

Ann Endocrinol (Paris) 2018 Dec 16;79(6):618-635. Epub 2018 Aug 16.

Service de médecine nucléaire, Inserm U970, Sorbonne université, groupe hospitalier Pitié-Salpétrière, 75013 Paris, France.

Treatment strategy in Graves' disease firstly requires recovery of euthyroid status by antithyroid therapy. Treatment modalities, precautions, advantages and side-effects are to be discussed with the patient. No particular treatment modality has demonstrated superiority. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.08.003DOI Listing
December 2018
7 Reads

Graves' disease in children.

Ann Endocrinol (Paris) 2018 Dec 16;79(6):647-655. Epub 2018 Aug 16.

Department of Pediatric Endocrinology and Diabetology and Reference Center for Rare Diseases of Thyroid and Hormone Receptivity, University hospital of Angers, 4, rue Larrey, 49933 Angers cedex 9, France. Electronic address:

R1 The diagnosis of Graves' disease in children is based on detecting a suppression of serum TSH concentrations and the presence of anti-TSH receptor antibodies. 1/+++. R2 Thyroid ultrasound is unnecessary for diagnosis, but can be useful for assessing the size and homogeneity of the goiter. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.08.001DOI Listing
December 2018
2 Reads

Graves' orbitopathy: Diagnosis and treatment.

Ann Endocrinol (Paris) 2018 Dec 23;79(6):656-664. Epub 2018 Aug 23.

Endocrinologie, cliniques universitaires Saint-Luc, université catholique de Louvain, 10, avenue Hippocrate, 1200 Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.08.005DOI Listing
December 2018

Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors.

Ann Endocrinol (Paris) 2018 Oct 1;79(5):574-582. Epub 2018 Aug 1.

CHU Dijon, service d'endocrinologie, diabétologie, maladies métaboliques, hôpital François-Mitterrand, 21034 Dijon cedex, France.

Tyrosine kinase inhibitors (TKI) interfere with glucose metabolism. Contrasting effects have been reported, even for a given molecule. Hyperglycemia rates range between 15 and 40%; nilotinib seems to be the molecule most liable to induce diabetes. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00034266183120
Publisher Site
http://dx.doi.org/10.1016/j.ando.2018.07.011DOI Listing
October 2018
19 Reads

Expert opinions on endocrine toxicity induced by new anticancer therapies: Precautions to be taken in performing and interpreting hormonal assays under immunotherapy.

Ann Endocrinol (Paris) 2018 Oct 11;79(5):550-554. Epub 2018 Jul 11.

Laboratoire d'hormonologie, service de biochimie et biologie moléculaire, CHU de Lyon, groupement hospitalier Est, 69008 Lyon, France.

As well as tyrosine kinase and mTOR inhibitors, new anticancer therapies make use of antibodies targeting tyrosine kinase receptors or blocking anti-tumor immune response checkpoints. These are always monoclonal; in their international non-proprietary names, the origin is prefixed to "-mab": e.g. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00034266183118
Publisher Site
http://dx.doi.org/10.1016/j.ando.2018.07.004DOI Listing
October 2018
2 Reads

Expert opinions on adrenal complications in immunotherapy.

Ann Endocrinol (Paris) 2018 Oct 11;79(5):539-544. Epub 2018 Jul 11.

Service d'endocrinologie-diabétologie-nutrition, hôpital Albert-Michallon, CHU de Grenoble, 38043 Grenoble cedex 9, France.

Primary adrenal insufficiency during immunotherapy is rare and does not warrant systematic screening during treatment. It should be suspected in case of typical clinical and biological presentation, but also in case of subclinical presentation with impaired general health status and/or hyponatremia. Diagnosis is based on low cortisol levels, measured at any time in case of emergency or else at 8 am, associated to elevated ACTH to rule out pituitary origin. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00034266183118
Publisher Site
http://dx.doi.org/10.1016/j.ando.2018.07.002DOI Listing
October 2018
8 Reads

Expert opinion on the metabolic complications of mTOR inhibitors.

Ann Endocrinol (Paris) 2018 Oct 23;79(5):583-590. Epub 2018 Aug 23.

Service d'endocrinologie, diabétologie, maladies métaboliques, CHU de Dijon, 2, boulevard du Maréchal-de-Lattre, BP 77908, 21000 Dijon, France; Unité Inserm, LNC-UMR 1231, université de Bourgogne, Dijon, France.

Using mTOR inhibitors (mTORi) as anticancer drugs led to hyperglycemia (12-50%) and hyperlipidemia (7-73%) in phase-III trials. These high rates require adapted treatment in cancer patients. Before initiating mTORi treatment, lipid profile screening should be systematic, with fasting glucose assay in non-diabetic patients and HbA in diabetic patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.07.010DOI Listing
October 2018
3 Reads

Expert opinion on immunotherapy induced diabetes.

Ann Endocrinol (Paris) 2018 Oct 25;79(5):545-549. Epub 2018 Jul 25.

Department of endocrinology, l'institut du thorax, CHU Nantes, 44000 Nantes, France.

Immunotherapy often incurs side-effects, mainly involving the skin, digestive tract and endocrine system. The most frequent endocrine side-effects involve the pituitary and thyroid glands. Cases of insulin-dependent diabetes, whether autoimmune or not (type 1 or 1B) have been reported with PD-1/PD-L1 inhibitors, alone or in association with anti-CTLA-4 antibodies, and were systematically associated with sudden-onset insulinopenia, frequently leading to ketoacidosis or fulminant diabetes, requiring first-line insulin therapy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00034266183118
Publisher Site
http://dx.doi.org/10.1016/j.ando.2018.07.006DOI Listing
October 2018
11 Reads

Expert opinion on thyroid complications in immunotherapy.

Ann Endocrinol (Paris) 2018 Oct 25;79(5):555-561. Epub 2018 Jul 25.

Service d'Endocrinologie, CHRU de Lille, Hôpital Huriez, 59037 Lille cedex, France.

Thyroid pathologies are the most common forms of endocrinopathy under anticancer immunotherapy. Frequency ranges from 3% to 22% for hypothyroidism and 1% to 11% for thyrotoxicosis. Risk is higher with anti-PD-1 than anti-CTLA-4 treatment and higher again with associated treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.07.007DOI Listing
October 2018
2 Reads

Expert opinion on thyroid complications of new anti-cancer therapies: Tyrosine kinase inhibitors.

Ann Endocrinol (Paris) 2018 Oct 11;79(5):569-573. Epub 2018 Jul 11.

Service d'endocrinologie, CHU de Rangueil-Larrey, 31059 Toulouse, France.

Thyroid pathology is the most frequent form of endocrinopathy during tyrosine kinase inhibitor (TKI) treatment. Dysthyroidism occurs in 10% to 80% of cases, depending on diagnostic criteria. In patients with intact thyroid gland prior to TKI treatment, incidence of dysthyroidism is 30-40%, with subclinical presentation in half of cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.07.003DOI Listing
October 2018

Expert opinion on pituitary complications in immunotherapy.

Ann Endocrinol (Paris) 2018 Oct 25;79(5):562-568. Epub 2018 Jul 25.

Service d'Endocrinologie, CHRU de Lille, Hopital Huriez, 59037 Lille cedex, France.

Hypophysitis is a frequent toxic endocrine side-effect of immunotherapy. Prevalence is higher with anti-CTLA-4 antibodies (4-20%) or in association with PD-1 inhibitors (8%). Diagnosis is presumptive, based on poorly specific clinical symptoms (usually, headache and asthenia) and/or hyponatremia and/or at least one pituitary deficit and/or abnormal imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.07.008DOI Listing
October 2018
3 Reads

Introduction to expert opinion on endocrine complications of new anticancer therapies.

Ann Endocrinol (Paris) 2018 Oct 11;79(5):535-538. Epub 2018 Jul 11.

Fédération d'Endocrinologie, Hospices Civils de Lyon, université Claude-Bernard Lyon 1, HESPER EA 7425, 69008 Lyon, France.

Over the last 10 years, cancer treatment has progressed, with increasing use of tyrosine kinase inhibitors, mTOR inhibitors and, most recently, immunotherapy. These molecules, however, also incur side-effects, including endocrine toxicity. As their indications are constantly increasing, due to proven efficacy, it is important for endocrinologists to know how to monitor and manage such toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.07.001DOI Listing
October 2018
2 Reads

Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions.

Ann Endocrinol (Paris) 2018 Oct 11;79(5):591-595. Epub 2018 Jul 11.

HESPER EA 7425, université Claude-Bernard Lyon 1, hospices civils de Lyon, fédération d'endocrinologie, 69008 Lyon, France.

The present final consensus statement of the French Society of Endocrinology lays out the assessments that are to be systematically performed before and during anticancer treatment by immunotherapy, tyrosine kinase inhibitors or mTOR inhibitors, even without onset of any endocrinopathy. It also discusses the CTCAE adverse event grading system in oncology and the difficulty of implementing it for endocrine side-effects of these anticancer treatments. Notably, this is why certain treatment steps applied in other side-effects (e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.07.005DOI Listing
October 2018
24 Reads

35 Congrès de la Société française d'endocrinologie (SFE) Nancy 2018.

Ann Endocrinol (Paris) 2018 09 23;79(4):191. Epub 2018 Jul 23.

Hospices civils de Lyon, 69000 Lyon, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.06.002DOI Listing
September 2018
7 Reads

Examining the therapeutic potential of various stem cell sources for differentiation into insulin-producing cells to treat diabetes.

Ann Endocrinol (Paris) 2019 Feb 21;80(1):47-53. Epub 2018 Jul 21.

Department of Endocrinology, the Second Affiliated Hospital of Nanchang University, No. 1, Minde Road, 330006 Nanchang, Jiangxi Province, China. Electronic address:

Novel strategies are being developed to generate stem-cell-derived insulin-producing cells (IPCs), which could reverse the growing incidence of diabetes worldwide. We reviewed studies of stem-cell-based therapies for pancreatic β-cell regeneration published between 1997 and 2017. Differentiation into IPCs can be achieved using various stem-cell sources: embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and several types of adult stem cells such as pancreatic, hepatic and mesenchymal stem cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.06.1084DOI Listing
February 2019
2 Reads

Genomic insights into Cushing syndrome.

Authors:
Guillaume Assié

Ann Endocrinol (Paris) 2018 Jun 4;79(3):119-122. Epub 2018 May 4.

Service d'endocrinologie, centre de référence des maladies rares de la surrénale, Assistance publique-Hôpitaux de Paris, hôpital Cochin, 75014 Paris, France; Inserm U1016, CNRS 8104, institut Cochin, université Paris Descartes, 75014 Paris, France. Electronic address:

In the setting of Cushing syndrome, genomic analyses can be performed either in tumors responsible for endogenous Cushing, or in patients exposed to glucocorticoid excess. Genomics of tumors identified several new genes - including ZNRF3 in adrenocortical carcinomas, PRKACA in cortisol-producing adrenal adenomas, ARMC5 in primary macronodular adrenal hyperplasia and USP8 in pituitary corticotroph adenomas. These genes shed new lights on the mechanisms responsible for these tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.03.011DOI Listing
June 2018
1 Read

Plasma glucose to glycated hemoglobin ratio: Method of differentiating fulminant type 1 diabetes from diabetic ketoacidosis.

Ann Endocrinol (Paris) 2019 Feb 3;80(1):16-20. Epub 2018 May 3.

Third Affiliated Hospital of Southern Medical University, department of endocrinology, Zhongshan Road West 183#, 510630 Guangzhou, Guangdong Province, China. Electronic address:

Objectives: In fulminant type 1 diabetes mellitus (fT1DM), plasma glucose (PG) levels are strongly increased, unlike glycated hemoglobin (HbA) levels, resulting in a sharply increased PG/HbA ratio. We investigated the PG/HbA ratio in fT1DM and tested the accuracy of cutoff points to easily and efficiently differentiate fT1DM from diabetic ketoacidosis (DKA).

Methods: We report 41 cases of fT1DM in which PG/HbA ratio was studied as a novel clinical parameter to predict fT1DM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.01.006DOI Listing
February 2019

Glucocorticoid receptor modulators.

Ann Endocrinol (Paris) 2018 Jun 3;79(3):107-111. Epub 2018 May 3.

Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.

The glucocorticoid hormone cortisol acts throughout the body to support circadian processes and adaptation to stress. The glucocorticoid receptor is the target of cortisol and of synthetic glucocorticoids, which are used widely in the clinic. Both agonism and antagonism of the glucocorticoid receptor may be beneficial in disease, but given the wide expression of the receptor and involvement in various processes, beneficial effects are often accompanied by unwanted side effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.03.004DOI Listing
June 2018
1 Read

The difficulties of pseudo-Cushing's syndrome (or "non-neoplastic hypercortisolism").

Authors:
Olivier Chabre

Ann Endocrinol (Paris) 2018 Jun 30;79(3):138-145. Epub 2018 Apr 30.

Service d'endocrinologie, faculté de médecine, unité mixte Inserm-CEA-UJF U1036 CEA, université Grenoble-Alpes, centre hospitalier universitaire Grenoble-Alpes, 38043 Grenoble, France. Electronic address:

Pseudo-Cushing's syndrome covers different pathological conditions responsible for mild-to-moderate ACTH-dependent hypercortisolism, related not to an ACTH-secreting tumor but rather to CRH and/or AVP hypothalamic secretion through activation of various neural pathways, in patients generally displaying excess central adiposity. It is better termed "non-neoplastic hypercortisolism" (NNH). The main conditions implicated in NNH comprise: neuropsychiatric disorder, alcohol abuse, insulin-resistant obesity, polycystic ovary syndrome, and end-stage kidney disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.04.017DOI Listing
June 2018
35 Reads

Acute adrenal crisis and mortality in adrenal insufficiency: Still a concern in 2018!

Authors:
Stefanie Hahner

Ann Endocrinol (Paris) 2018 Jun 30;79(3):164-166. Epub 2018 Apr 30.

Department of medicine I, endocrinology and diabetology, Würzburg University Hospital, Oberdürrbacher street, 6, 97080 Würzburg, Germany. Electronic address:

Despite established replacement therapy, mortality in patients suffering from chronic adrenal insufficiency is increasing. This may be partly explained by the fact that lack of adrenal stress hormones impairs the body's capacity to deal adequately with stress situations, resulting in life-threatening adrenal crises. Since many such situations are of rapid onset, concepts that allow for quick response to emergencies are particularly important. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ando.2018.04.015DOI Listing
June 2018
31 Reads